Limiting Radiation Fields in Treating Early-Stage Hodgkin Lymphoma

Involved-nodal irradiation might be a safe alternative to involved-field irradiation.

Very high rates of progression-free survival (PFS) and overall survival (OS) are achieved with limited cycles of chemotherapy plus radiation therapy (RT) in patients with early-stage Hodgkin lymphoma (HL). Recent trials showed that, compared with extended-field irradiation, limited-field irradiation achieved similarly high cure rates in HL patients and diminished risks for late second malignancies and cardiovascular complications.

To evaluate the efficacy of involved-nodal irradiation in this population, investigators conducted a retrospective analysis of 325 adult patients in British Columbia who had early-stage HL (29% stage IA disease, 71% stage IIA disease; median age at diagnosis, 35). Patients were staged by computed tomography scan. T…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee